{"id":"NCT00360334","sponsor":"AstraZeneca","briefTitle":"A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients","officialTitle":"An Open Label Study Comparing Exenatide With Basal Insulin in Achieving an HbA1c of ≤ 7.4% With Minimum Weight Gain, in Type 2 Diabetes Patients Who Are Not Achieving Adequate HbA1c Control on Oral Anti Diabetic Therapies Alone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06","primaryCompletion":"2008-04","completion":"2008-04","firstPosted":"2006-08-04","resultsPosted":"2009-06-05","lastUpdate":"2015-04-07"},"enrollment":235,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"exenatide","otherNames":["Byetta"]},{"type":"DRUG","name":"insulin glargine","otherNames":["Lantus"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"This is a phase 3 trial designed to compare the effects of twice daily exenatide plus oral antidiabetic agents (OADs) and once-daily insulin glargine plus OADs with respect to glycemic control, as measured by hemoglobin A1c, with minimum weight gain, in patients with uncontrolled type 2 diabetes on OADs.","primaryOutcome":{"measure":"Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg)","timeFrame":"26 weeks","effectByArm":[{"arm":"Exenatide","deltaMin":53.4,"sd":null},{"arm":"Insulin Glargine","deltaMin":19.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":31,"countries":["United Kingdom"]},"refs":{"pmids":["19930005","22913891"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5},"commonTop":["Nausea","Nasopharyngitis","Diarrhoea","Headache","Vomiting"]}}